Rani Therapeutics Holdings, Inc.
RANI
$1.10
$0.0010.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.55% | -12.37% | -10.68% | -4.88% | -1.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.40% | -26.17% | -15.72% | -3.88% | 4.17% |
| Operating Income | 24.96% | 26.17% | 15.72% | 3.88% | -4.17% |
| Income Before Tax | 16.64% | 22.88% | 12.53% | 0.77% | -7.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.64% | 22.84% | 12.34% | 0.78% | -7.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -21.66% | -24.68% | -13.53% | -2.56% | 3.53% |
| Net Income | 11.63% | 21.00% | 11.14% | -1.05% | -11.06% |
| EBIT | 24.96% | 26.17% | 15.72% | 3.88% | -4.17% |
| EBITDA | 25.59% | 26.78% | 16.25% | 4.31% | -3.77% |
| EPS Basic | 20.87% | 25.22% | 14.27% | 2.54% | -4.03% |
| Normalized Basic EPS | 29.67% | 20.47% | 11.69% | -3.19% | -18.48% |
| EPS Diluted | 20.87% | 25.22% | 14.27% | 2.54% | -4.03% |
| Normalized Diluted EPS | 29.67% | 20.47% | 11.69% | -3.19% | -18.48% |
| Average Basic Shares Outstanding | 11.64% | 5.96% | 3.82% | 3.85% | 7.20% |
| Average Diluted Shares Outstanding | 11.64% | 5.96% | 3.82% | 3.85% | 7.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |